Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics Inc. (VIRX) is a clinical-stage biopharmaceutical company pioneering viral gene activation therapies for Epstein-Barr virus (EBV)-associated cancers. This page serves as the definitive source for Viracta news, providing investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate strategy.
Access consolidated information about Viracta's precision oncology programs, including progress on Nana-val – its investigational oral therapy combining nanatinostat and valganciclovir. The news collection covers essential updates, trial design modifications, and strategic operational decisions impacting the company's trajectory in viral oncology research.
Key content categories include clinical trial results, FDA communications, partnership announcements, and corporate restructuring updates. All materials maintain factual accuracy while avoiding speculative analysis, adhering to financial content compliance standards.
Bookmark this page for streamlined access to Viracta's latest developments in targeting EBV-positive malignancies through innovative epigenetic approaches. Check regularly for authoritative updates on this clinical-stage company's progress in addressing unmet needs in virus-associated cancers.
Viracta Therapeutics (Nasdaq: VIRX), a precision oncology company, announces participation in the Stifel 2023 Targeted Oncology Days on April 26, 2023. President and CEO Mark Rothera and Chief Medical Officer Lisa Rojkjaer, M.D. will conduct a virtual fireside chat at 12:00 p.m. ET. A live webcast will be accessible on the Investors section of Viracta's website and archived for 90 days.
Viracta focuses on treating virus-associated cancers globally. Its lead product candidate, nanatinostat, is part of an oral combination therapy with valganciclovir (Nana-val), targeting subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma and EBV+ nasopharyngeal carcinoma in ongoing clinical trials.
Viracta Therapeutics (Nasdaq: VIRX) announced the pivotal NAVAL-1 study of Nana-val in EBV-positive lymphoma has opened at 70 global sites, with updates expected in H1 2023. The company completed initial enrollment for the fourth dose level in its Phase 1b/2 trial for advanced EBV-positive solid tumors, anticipating complete data by year's end. They secured orphan drug designation from the European Commission for Nana-val targeting diffuse large B-cell lymphoma. As of December 31, 2022, cash reserves stood at $91 million, providing a runway into late 2024, supporting ongoing clinical development initiatives.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology firm, announced that President Mark Rothera and CMO Lisa Rojkjaer will participate in a virtual fireside chat at the 33rd Annual Oppenheimer Healthcare Conference on March 15, 2023, at 12:00 p.m. ET. The event will be webcast live on the Investors section of their website and archived for 30 days. Viracta focuses on treating and preventing virus-associated cancers, with its lead product candidate, Nana-val, being evaluated in clinical trials for EBV-positive lymphomas and nasopharyngeal carcinoma.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced that President and CEO Mark Rothera will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET. The presentation will focus on the company's advancements in treating virus-associated cancers.
A live webcast will be available on the Investors section of the Viracta website and archived for 30 days. Viracta's lead product candidate, Nana-val, is an investigational oral therapy currently evaluated in multiple clinical trials, including treatments for EBV-positive lymphoma and nasopharyngeal carcinoma.
Viracta Therapeutics has received its sixth orphan drug designation for Nana-val (nanatinostat and valganciclovir) from the European Commission for treating diffuse large B-cell lymphoma (DLBCL). This follows prior designations in the U.S. for various lymphoma types, highlighting a significant market need for treatments targeting EBV-positive malignancies. Nana-val's pivotal trial, NAVAL-1, spans over 60 global sites, aimed at addressing the unmet clinical demand. The orphan drug designation offers market exclusivity and regulatory benefits, promoting the development of treatments for rare diseases. Viracta remains focused on expanding its clinical trials and enhancing treatment options for patients.
Viracta Therapeutics announces preliminary data from its Phase 1b/2 trial of Nana-val, showing a partial response in EBV+ recurrent/metastatic nasopharyngeal carcinoma (NPC). The company is currently enrolling patients in the fourth dose level, with no reported dose-limiting toxicities. Viracta ended 2022 with over $90 million in cash, ensuring a runway into late 2024. The 2023 objectives include updates on the NAVAL-1 study and advancing Nana-val’s development across EBV+ solid tumors. The ongoing clinical trials and strong financial position position Viracta well for future milestones.
Viracta Therapeutics has reported preliminary results from its Phase 1b/2 study of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma (NPC). Data from the first two dose levels showed the treatment was well tolerated with no dose-limiting toxicities. Of the evaluable patients, two achieved stable disease. The trial is currently in dose escalation, with plans to initiate the Phase 2 expansion in the second half of 2023. This study aims to optimize dosing for future treatment of EBV-associated cancers.
